Author

M. Nagaoka

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Yoshimura· 1 shared C. Nishiyama· 1 shared C. Nishizawa-Harada· 1 shared C.-T. Huang· 1 shared D. L. Jarvis· 1 shared H. Mabashi-Asazuma· 1 shared I. Kimura-Takagi· 1 shared I. Yokoseki· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Yoshimura

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

NR4A3 deficiency ameliorates contact hypersensitivity and exacerbates psoriasis by regulating gene expression in dendritic cells

M. Katagiri, N. Ito, K. Nagata, S. Nakano, N. Minamikawa, N. Yamashita, M. Takahashi, M. Kurihara, M. Nagaoka, M. Ando, T. Ito, T. Yashiro, A. Yoshimura, C. Nishiyama

This study shows NR4A3 deficiency reduces contact hypersensitivity but worsens psoriasis by altering dendritic cell gene expression.

bioRxiv · Feb 20, 2024 · PreprintImmunology

ncBAF, a chromatin remodeler, enhances PXR-mediated transcriptional activation in the human and mouse liver

K. Kurosawa, M. Nakano, I. Yokoseki, M. Nagaoka, S. Takemoto, Y. Sakai, K. Kobayashi, Y. Kazuki, T. Fukami, M. Nakajima

This study shows that inhibiting BRD9, a component of ncBAF, reduces PXR-mediated transcriptional activation and associated adverse effects in liver cells and mice.

bioRxiv · Feb 3, 2023 · PreprintPharmacology & Toxicology

Development of an orally-administrable tumor vasculature-targeting therapeutic using annexin A1-binding D-peptides

M. N. Fukuda, M. Nonaka, H. Mabashi-Asazuma, D. L. Jarvis, K. Yamasaki, T. Akama, M. Nagaoka, T. Sasai, I. Kimura-Takagi, Y. Suwa, T. Yaegashi, C.-T. Huang, C. Nishizawa-Harada

The paper develops an orally-administrable therapeutic using annexin A1-binding D-peptides to target tumor vasculature, showing suppression of brain tumor growth in mice.

PLOS ONE · Jan 6, 2021Peer-reviewedPharmacology & Toxicology